Unicycive Therapeutics, Inc. (UNCY) Form 8-K — Aug 12, 2026
Unicycive Therapeutics reported a Q2 2026 net loss of $1.7 million, or $(0.06) per share, narrowed from a $6.5 million loss ($(0.52) per share) a year earlier, driven primarily by $8.4 million of other income from the change in fair value of its warrant liability. R&D expense rose to $2.8 million and G&A expense to $7.4 million, reflecting higher stock compensation and commercial launch preparation. On the regulatory front, the FDA assigned a facility inspection to the third-party manufacturing vendor of lead candidate oxylanthanum carbonate (OLC), and Unicycive expects to resubmit its New Drug Application assuming a successful inspection.
Key figures
- Total Assets
- 72029000
- Cash Position
- 61400000
- Shares Outstanding
- 27855257
- Cash runway
- expected into 2027
- Crl received
- June 2026 (same deficiencies as June 2025 CRL)
- Net loss q2 2025
- -$6.5 million
- Ga expense q2 2025
- $5.2 million
- Ga expense q2 2026
- $7.4 million
- Rd expense q2 2025
- $1.8 million
- Rd expense q2 2026
- $2.8 million
- Cash and equivalents
- $44,185 thousand
- Other income q2 2026
- $8.4 million
- Marketable securities
- $17,240 thousand
- Shares outstanding dec31 2025
- 22114245
- Warrant liability fair value gain
- $7,977 thousand
Price after filing
Close on the filing date to close N calendar days later (from $5.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.